Galectin Therapeutics (GALT) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Galectin Therapeutics (NASDAQ:GALT) from a sell rating to a hold rating in a report released on Tuesday morning.
According to Zacks, “Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Galectin Therapeutics, formerly known as Pro-Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. “
A number of other equities research analysts have also commented on GALT. Roth Capital started coverage on Galectin Therapeutics in a research report on Thursday, October 19th. They set a buy rating and a $8.00 price objective for the company. HC Wainwright raised their price objective on Galectin Therapeutics from $3.50 to $6.00 and gave the stock a buy rating in a research report on Tuesday, November 28th. Finally, ValuEngine lowered Galectin Therapeutics from a sell rating to a strong sell rating in a research report on Friday, December 1st. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Galectin Therapeutics has a consensus rating of Buy and a consensus target price of $5.55.
In other news, major shareholder Fund L.P. 10X sold 244,444 shares of the firm’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $5.43, for a total transaction of $1,327,330.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James C. Czirr sold 205,144 shares of the firm’s stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $5.45, for a total value of $1,118,034.80. The disclosure for this sale can be found here. 38.80% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Wedbush Securities Inc. purchased a new stake in shares of Galectin Therapeutics during the 4th quarter worth about $102,000. Northern Trust Corp raised its stake in shares of Galectin Therapeutics by 4.4% during the 2nd quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after purchasing an additional 3,176 shares in the last quarter. Virtu KCG Holdings LLC raised its stake in shares of Galectin Therapeutics by 24.4% during the 2nd quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after purchasing an additional 21,008 shares in the last quarter. Advisor Group Inc. raised its stake in shares of Galectin Therapeutics by 7.4% during the 3rd quarter. Advisor Group Inc. now owns 519,850 shares of the company’s stock worth $1,112,000 after purchasing an additional 35,850 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Galectin Therapeutics by 18.2% during the 2nd quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after purchasing an additional 134,165 shares in the last quarter. 10.66% of the stock is owned by institutional investors.
WARNING: “Galectin Therapeutics (GALT) Upgraded at Zacks Investment Research” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/galectin-therapeutics-galt-upgraded-at-zacks-investment-research/1856977.html.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.